NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-.

Cover of StatPearls

StatPearls [Internet].

Show details

Physiology, Renin Angiotensin System

; .

Author Information

Last Update: July 22, 2021.


The renin–angiotensin–aldosterone system (RAAS) is a critical regulator of blood volume and systemic vascular resistance. While the baroreceptor reflex responds in a short-term manner to decreased arterial pressure, the RAAS is responsible for more chronic alterations. It is composed of three major compounds: renin, angiotensin II, and aldosterone. These three act to elevate arterial pressure in response to decreased renal blood pressure, decreased salt delivery to the distal convoluted tubule, and/or beta-agonism. Through these mechanisms, the body can elevate the blood pressure in a prolonged manner.[1][2][3]

Organ Systems Involved

The RAAS involves the kidneys, lungs, systemic vasculature, and the brain.


The RAAS functions to elevate blood volume and arterial tone in a prolonged manner. It does this by increasing sodium reabsorption, water reabsorption, and vascular tone.


Within the afferent arterioles of the kidney, specialized cells called juxtaglomerular (JG) cells contain prorenin. While prorenin is secreted constitutively in its inactive form, activation of JG cells causes the cleavage of prorenin to renin. Activation of these cells occurs in response to decreased blood pressure, beta-activation, or activation by macula densa cells in response to a decreased sodium load in the distal convoluted tubule.[4][5]

Once renin has been released into the blood, it can act on its target, angiotensinogen. Angiotensinogen is produced in the liver and is found continuously circulating in the plasma. Renin then acts to cleave angiotensinogen into angiotensin I. Angiotensin I is physiologically inactive, but acts as a precursor for angiotensin II.

The conversion of angiotensin I to angiotensin II is catalyzed by an enzyme called angiotensin converting enzyme (ACE). ACE is found primarily in the vascular endothelium of the lungs and kidneys. After angiotensin I is converted to angiotensin II, it has effects on the kidney, adrenal cortex, arterioles, and brain by binding to angiotensin II type I (AT) and type II (AT) receptors. The effects discussed below are a result of binding to AT receptors. The role of AT receptors is still being investigated, but pertinently, they have been shown to cause vasodilation by nitric oxide generation. In the plasma, angiotensin II has a half-life of 1-2 minutes, at which point peptidases degrade it into angiotensin III and IV. Angiotensin III has been shown to have 100% of the aldosterone stimulating effect of angiotensin II, but 40% of the pressor effects, while angiotensin IV has further decreased the systemic effect.

In the proximal convoluted tubule of the kidney, angiotensin II acts to increase Na-H exchange, increasing sodium reabsorption. Increased levels of Na in the body acts to increase the osmolarity of the blood, leading to a shift of fluid into the blood volume and extracellular space (ECF). This increases the arterial pressure of the patient.

Angiotensin II also acts on the adrenal cortex, specifically the zona glomerulosa. Here, it stimulates the release of aldosterone. Aldosterone is a steroid hormone that causes an increase in sodium reabsorption and potassium excretion at the distal tubule and collecting duct of the nephron. Aldosterone works by stimulating the insertion of luminal Na channels and basolateral Na-K ATPase proteins. The net effect is an increased level of sodium reabsorption. This has the same effect as mentioned previously: the increased total body sodium leads to an increase in osmolarity and subsequent increase in blood and ECF volume. In contrast to angiotensin II, aldosterone is a steroid hormone. As a result, it enacts change by binding to nuclear receptors and altering gene transcription. Thus, the effects of aldosterone may take hours to days to begin, while the effects of angiotensin II are rapid.

The effect of angiotensin II on vasoconstriction takes place in systemic arterioles. Here, angiotensin II binds to G protein-coupled receptors, leading to a secondary messenger cascade that results in potent arteriolar vasoconstriction. This acts to increase total peripheral resistance, causing an increase in blood pressure.

Finally, angiotensin II acts on the brain. Here, it has three effects. First, it binds to the hypothalamus, stimulating thirst and increased water intake. Second, it stimulates the release of antidiuretic hormone (ADH) by the posterior pituitary. ADH, or vasopressin, acts to increase water reabsorption in the kidney by inserting aquaporin channels at the collecting duct. Finally, angiotensin II decreases the sensitivity of the baroreceptor reflex. This diminishes baroreceptor response to an increase in blood pressure, which would be counterproductive to the goal of the RAAS.

The net effect of these interactions is an increase in total body sodium, total body water, and vascular tone.

Clinical Significance

The RAAS acts to manage blood volume and arteriolar tone on a long-term basis. While minor and rapid shifts are typically managed via the baroreceptor reflex, the RAAS can alter blood volume chronically. Though the RAAS serves a critical function, it can be activated inappropriately in several conditions that may then lead to the development of hypertension. For example, renal artery stenosis results in a decreased volume of blood reaching one (or both) kidneys. As a result, the juxtaglomerular cells will sense a decrease in blood volume, activating the RAAS. This can lead to an inappropriate elevation of circulating blood volume and arteriolar tone due to poor renal perfusion.[6][7]

Pharmacologically, the RAAS is a frequently manipulated system in the management of heart failure, hypertension, diabetes mellitus, and acute myocardial infarction. ACE inhibitors (e.g., enalapril), angiotensin receptor blockers (ARBs, e.g., losartan), and aldosterone antagonists (e.g., spironolactone) all act to decrease the effect of the RAAS.

The varied mechanisms of these drugs allow their utilization in different scenarios. ACE inhibitors inhibit the action of angiotensin-converting enzymes, thus decreasing the production of angiotensin II. ARBs act to block AT receptors, thus inhibiting angiotensin’s effect while maintaining normal levels of the compound. Aldosterone inhibitors have two specific varieties. The first (e.g., spironolactone or eplerenone) act as aldosterone antagonists. These work by preventing the binding of aldosterone to binding sites in the kidney, preventing insertion of Na channels. The second (e.g., amiloride or triamterene) group act to block the inserted Na channels in the distal convoluted tubule.

A common use for ACE inhibitors or ARBs is in the management of hypertension. In these cases, blocking or decreasing levels of angiotensin II will lead to a reduction in blood pressure. They achieve this goal by decreasing sodium and water reabsorption, leading to a reduction in blood volume, and decreasing arteriolar tone. In addition, these drugs are often used in the management of diabetes mellitus. Patients with diabetes mellitus often have renal manifestations such as proteinuria due to excess glucose damaging the glomerulus. Using ACE inhibitors or ARBs can decrease efferent arteriolar tone, leading to a reduction in pressure on the glomerulus. Thus, they are frequently used for prevention of worsening diabetic nephropathy.

Review Questions


Liu J, Zhou Y, Liu Y, Li L, Chen Y, Liu Y, Feng Y, Yosypiv IV, Song R, Peng H. (Pro)renin receptor regulates lung development via the Wnt/β-catenin signaling pathway. Am J Physiol Lung Cell Mol Physiol. 2019 Aug 01;317(2):L202-L211. [PMC free article: PMC6734386] [PubMed: 31042081]
Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME. Obesity, kidney dysfunction and hypertension: mechanistic links. Nat Rev Nephrol. 2019 Jun;15(6):367-385. [PMC free article: PMC7278043] [PubMed: 31015582]
Drummond GR, Vinh A, Guzik TJ, Sobey CG. Immune mechanisms of hypertension. Nat Rev Immunol. 2019 Aug;19(8):517-532. [PubMed: 30992524]
Ren L, Lu X, Danser AHJ. Revisiting the Brain Renin-Angiotensin System-Focus on Novel Therapies. Curr Hypertens Rep. 2019 Apr 04;21(4):28. [PMC free article: PMC6449495] [PubMed: 30949864]
Nehme A, Zouein FA, Zayeri ZD, Zibara K. An Update on the Tissue Renin Angiotensin System and Its Role in Physiology and Pathology. J Cardiovasc Dev Dis. 2019 Mar 29;6(2) [PMC free article: PMC6617132] [PubMed: 30934934]
Sztechman D, Czarzasta K, Cudnoch-Jedrzejewska A, Szczepanska-Sadowska E, Zera T. Aldosterone and mineralocorticoid receptors in regulation of the cardiovascular system and pathological remodelling of the heart and arteries. J Physiol Pharmacol. 2018 Dec;69(6) [PubMed: 30898981]
Santos RAS, Oudit GY, Verano-Braga T, Canta G, Steckelings UM, Bader M. The renin-angiotensin system: going beyond the classical paradigms. Am J Physiol Heart Circ Physiol. 2019 May 01;316(5):H958-H970. [PMC free article: PMC7191626] [PubMed: 30707614]
Copyright © 2021, StatPearls Publishing LLC.

This book is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits use, duplication, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, a link is provided to the Creative Commons license, and any changes made are indicated.

Bookshelf ID: NBK470410PMID: 29261862


  • PubReader
  • Print View
  • Cite this Page

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Similar articles in PubMed

See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...